4-186082920-C-T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_003265.3(TLR3):​c.1234C>T​(p.Leu412Phe) variant causes a missense change. The variant allele was found at a frequency of 0.284 in 1,613,766 control chromosomes in the GnomAD database, including 67,672 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L412V) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.24 ( 5155 hom., cov: 32)
Exomes 𝑓: 0.29 ( 62517 hom. )

Consequence

TLR3
NM_003265.3 missense

Scores

4
8
6

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:9

Conservation

PhyloP100: 4.10

Publications

454 publications found
Variant links:
Genes affected
TLR3 (HGNC:11849): (toll like receptor 3) The protein encoded by this gene is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLRs are highly conserved from Drosophila to humans and share structural and functional similarities. They recognize pathogen-associated molecular patterns (PAMPs) that are expressed on infectious agents, and mediate the production of cytokines necessary for the development of effective immunity. The various TLRs exhibit different patterns of expression. This receptor is most abundantly expressed in placenta and pancreas, and is restricted to the dendritic subpopulation of the leukocytes. It recognizes dsRNA associated with viral infection, and induces the activation of NF-kappaB and the production of type I interferons. It thus plays a role in host defense against multiple viruses. [provided by RefSeq, Jul 2021]
TLR3 Gene-Disease associations (from GenCC):
  • immunodeficiency 83, susceptibility to viral infections
    Inheritance: Unknown Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0021493137).
BP6
Variant 4-186082920-C-T is Benign according to our data. Variant chr4-186082920-C-T is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 41472.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.309 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TLR3NM_003265.3 linkc.1234C>T p.Leu412Phe missense_variant Exon 4 of 5 ENST00000296795.8 NP_003256.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TLR3ENST00000296795.8 linkc.1234C>T p.Leu412Phe missense_variant Exon 4 of 5 1 NM_003265.3 ENSP00000296795.3

Frequencies

GnomAD3 genomes
AF:
0.236
AC:
35941
AN:
151972
Hom.:
5148
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0691
Gnomad AMI
AF:
0.268
Gnomad AMR
AF:
0.313
Gnomad ASJ
AF:
0.249
Gnomad EAS
AF:
0.321
Gnomad SAS
AF:
0.246
Gnomad FIN
AF:
0.323
Gnomad MID
AF:
0.237
Gnomad NFE
AF:
0.298
Gnomad OTH
AF:
0.282
GnomAD2 exomes
AF:
0.279
AC:
70051
AN:
250924
AF XY:
0.280
show subpopulations
Gnomad AFR exome
AF:
0.0647
Gnomad AMR exome
AF:
0.299
Gnomad ASJ exome
AF:
0.256
Gnomad EAS exome
AF:
0.340
Gnomad FIN exome
AF:
0.325
Gnomad NFE exome
AF:
0.298
Gnomad OTH exome
AF:
0.288
GnomAD4 exome
AF:
0.289
AC:
421977
AN:
1461676
Hom.:
62517
Cov.:
55
AF XY:
0.287
AC XY:
208939
AN XY:
727126
show subpopulations
African (AFR)
AF:
0.0604
AC:
2023
AN:
33480
American (AMR)
AF:
0.298
AC:
13331
AN:
44716
Ashkenazi Jewish (ASJ)
AF:
0.257
AC:
6704
AN:
26132
East Asian (EAS)
AF:
0.299
AC:
11879
AN:
39698
South Asian (SAS)
AF:
0.240
AC:
20729
AN:
86232
European-Finnish (FIN)
AF:
0.323
AC:
17269
AN:
53394
Middle Eastern (MID)
AF:
0.247
AC:
1423
AN:
5766
European-Non Finnish (NFE)
AF:
0.298
AC:
331842
AN:
1111880
Other (OTH)
AF:
0.278
AC:
16777
AN:
60378
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.475
Heterozygous variant carriers
0
18187
36373
54560
72746
90933
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
10832
21664
32496
43328
54160
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.236
AC:
35960
AN:
152090
Hom.:
5155
Cov.:
32
AF XY:
0.238
AC XY:
17727
AN XY:
74334
show subpopulations
African (AFR)
AF:
0.0691
AC:
2868
AN:
41530
American (AMR)
AF:
0.314
AC:
4793
AN:
15270
Ashkenazi Jewish (ASJ)
AF:
0.249
AC:
863
AN:
3472
East Asian (EAS)
AF:
0.322
AC:
1664
AN:
5164
South Asian (SAS)
AF:
0.246
AC:
1184
AN:
4814
European-Finnish (FIN)
AF:
0.323
AC:
3411
AN:
10546
Middle Eastern (MID)
AF:
0.221
AC:
65
AN:
294
European-Non Finnish (NFE)
AF:
0.298
AC:
20272
AN:
67982
Other (OTH)
AF:
0.283
AC:
596
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1318
2635
3953
5270
6588
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
380
760
1140
1520
1900
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.276
Hom.:
27714
Bravo
AF:
0.227
TwinsUK
AF:
0.301
AC:
1117
ALSPAC
AF:
0.287
AC:
1105
ESP6500AA
AF:
0.0710
AC:
313
ESP6500EA
AF:
0.290
AC:
2496
ExAC
AF:
0.271
AC:
32913
Asia WGS
AF:
0.297
AC:
1036
AN:
3478
EpiCase
AF:
0.287
EpiControl
AF:
0.291

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Immunodeficiency 83, susceptibility to viral infections Benign:2
-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Nov 25, 2016
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Oct 29, 2019
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 29290528, 24371259, 26298326, 31445170, 28046022, 23240626, 17434873, 18325643, 22549436, 18753640, 20413676, 20472559, 20855885, 21093032, 19016379, 21216866, 22174453, 22537752, 22504413, 21712495, 25304972, 22024499) -

not specified Benign:1
Mar 28, 2016
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: MAF. Associated with susceptibility to infections, rheumatoid arthritis. Some functional evidence to show reduced IFN and TNF secretion in response to stimulation. This may be a risk allele, but unlikely to cause disease on its own -

Herpes simplex encephalitis, susceptibility to, 1 Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

TLR3-related disorder Benign:1
Jan 28, 2024
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Susceptibility to HIV infection Benign:1
Aug 08, 2018
OMIM
Significance:protective
Review Status:no assertion criteria provided
Collection Method:literature only

- -

Susceptibility to HIV infection;C2751803:Immunodeficiency 83, susceptibility to viral infections Benign:1
Aug 13, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.55
BayesDel_addAF
Benign
-0.31
T
BayesDel_noAF
Uncertain
-0.070
CADD
Uncertain
23
DANN
Uncertain
1.0
DEOGEN2
Benign
0.30
T;.;.
Eigen
Pathogenic
0.77
Eigen_PC
Uncertain
0.61
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Benign
0.85
T;D;D
MetaRNN
Benign
0.0021
T;T;T
MetaSVM
Benign
-1.4
T
MutationAssessor
Pathogenic
4.1
H;.;.
PhyloP100
4.1
PrimateAI
Uncertain
0.55
T
PROVEAN
Uncertain
-3.5
D;D;D
REVEL
Uncertain
0.45
Sift
Pathogenic
0.0
D;D;D
Sift4G
Uncertain
0.0070
D;D;D
Polyphen
1.0
D;.;.
Vest4
0.20
MPC
0.34
ClinPred
0.082
T
GERP RS
5.0
Varity_R
0.81
gMVP
0.57
Mutation Taster
=59/41
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs3775291; hg19: chr4-187004074; COSMIC: COSV57167912; COSMIC: COSV57167912; API